# Zivo Bioscience, Inc.: overview ZIVO · OTC · CIK 1101026 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/zivo.md) · [Financials](/companies/zivo/financials.md) · [Filings](/companies/zivo/filings.md) · [Insiders](/companies/zivo/insiders.md) Latest reported revenue: [$65.6k](/filings/0001654954-25-013095.md) for Q3 FY2025, three months to 2025-09-30, from the 10-Q filed Nov 14, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001654954-25-013095). ## Last eight quarters | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [11.8 d](/filings/0001654954-25-002948.md) | [35.7](/filings/0001654954-25-005748.md) | [0.0](/filings/0001654954-25-009650.md) | [31.5](/filings/0001654954-25-013095.md) | [90.0 d](/filings/0001654954-25-002948.md) | [0.0](/filings/0001654954-25-005748.md) | [53.4](/filings/0001654954-25-009650.md) | [65.6](/filings/0001654954-25-013095.md) | | Gross margin | % | [35.0% d](/filings/0001654954-25-002948.md) | [35.0%](/filings/0001654954-25-005748.md) | not reported | [30.0%](/filings/0001654954-25-013095.md) | [30.0% d](/filings/0001654954-25-002948.md) | not reported | [33.6%](/filings/0001654954-25-009650.md) | [32.4%](/filings/0001654954-25-013095.md) | | Operating margin | % | [(16072.8%) d](/filings/0001654954-25-002948.md) | [(3571.8%)](/filings/0001654954-25-005748.md) | not reported | [(7174.7%)](/filings/0001654954-25-013095.md) | [(1773.8%) d](/filings/0001654954-25-002948.md) | not reported | [(3057.8%)](/filings/0001654954-25-009650.md) | [(1551.8%)](/filings/0001654954-25-013095.md) | | Net margin | % | [(16174.1%) d](/filings/0001654954-25-002948.md) | [(3579.2%)](/filings/0001654954-25-005748.md) | not reported | [(7201.9%)](/filings/0001654954-25-013095.md) | [(1779.3%) d](/filings/0001654954-25-002948.md) | not reported | [(3071.6%)](/filings/0001654954-25-009650.md) | [(1574.2%)](/filings/0001654954-25-013095.md) | | Diluted EPS | $ per share | not reported | [(0.47)](/filings/0001654954-25-005748.md) | [(2.78)](/filings/0001654954-25-009650.md) | [(0.67)](/filings/0001654954-25-013095.md) | not reported | [(1.12)](/filings/0001654954-25-005748.md) | [(0.43)](/filings/0001654954-25-009650.md) | [(0.27)](/filings/0001654954-25-013095.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [20.0](/filings/0001654954-22-005298.md) | [0.0](/filings/0001654954-23-002845.md) | [0.0](/filings/0001654954-24-003228.md) | [27.7](/filings/0001654954-25-002948.md) | [157](/filings/0001654954-25-002948.md) | | Gross margin | % | not reported | not reported | not reported | [42.0%](/filings/0001654954-25-002948.md) | [31.1%](/filings/0001654954-25-002948.md) | | Operating margin | % | [(42778.4%)](/filings/0001654954-22-005298.md) | not reported | not reported | [(26267.7%)](/filings/0001654954-25-002948.md) | [(8498.9%)](/filings/0001654954-25-002948.md) | | Net margin | % | [(45528.6%)](/filings/0001654954-22-005298.md) | not reported | not reported | [(28127.2%)](/filings/0001654954-25-002948.md) | [(8513.4%)](/filings/0001654954-25-002948.md) | | Diluted EPS | $ per share | [(0.02)](/filings/0001078782-21-000172.md) | not reported | not reported | [(4.60)](/filings/0001654954-25-002948.md) | [(4.23)](/filings/0001654954-25-002948.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/zivo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CoreCap Advisors, LLC](/funds/1902501.md) | 2026-06-30 | $17.6k | 4,360 | | Unchanged | ## Recent filings [All 618 filings](/companies/zivo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-03-30 | 08:01 ET | [8-K](/filings/0001654954-26-002928.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001654954-26-002928 | | 2026-02-27 | 20:20 ET | [SCHEDULE 13D/A](/filings/0001213900-26-021894.md) | Ownership report, active investor, amended | 0001213900-26-021894 | | 2025-12-23 | 16:06 ET | [8-K](/filings/0001654954-25-014296.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001654954-25-014296 | | 2025-11-14 | 16:39 ET | [10-Q](/filings/0001654954-25-013095.md) | Quarterly report, period 2025-09-30 | 0001654954-25-013095 | | 2025-09-10 | 09:49 ET | [8-K](/filings/0001654954-25-010579.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001654954-25-010579 | | 2025-08-18 | 16:12 ET | [8-K](/filings/0001654954-25-009772.md) | 5.02 Departure or appointment of officers or directors | 0001654954-25-009772 | | 2025-08-14 | 16:21 ET | [10-Q](/filings/0001654954-25-009650.md) | Quarterly report, period 2025-06-30 | 0001654954-25-009650 | | 2025-07-14 | 16:59 ET | [8-K](/filings/0001654954-25-008035.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001654954-25-008035 | | 2025-06-11 | 16:10 ET | [8-K](/filings/0001654954-25-006837.md) | 5.07 Shareholder vote results | 0001654954-25-006837 | | 2025-05-15 | 16:10 ET | [10-Q](/filings/0001654954-25-005748.md) | Quarterly report, period 2025-03-31 | 0001654954-25-005748 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2024](/filings/0001654954-25-002948.md), filed Mar 18, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1101026 - Tickers: ZIVO - Exchange: OTC - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.